Neurological Sciences

, Volume 38, Issue 5, pp 811–817 | Cite as

Serum levels of homocysteine at admission are associated with post-stroke depression in acute ischemic stroke

Original Article

Abstract

The primary purpose of this study was to assess the serum levels of homocysteine (HCY) at admission to the presence of post-stroke depression (PSD). From September 2014 to December 2015, first-ever acute ischemic stroke patients within the first 24 h after stroke onset were consecutively recruited and followed-up for 3 months. Based on the symptoms, diagnoses of depression were made in accordance with DSM-IV criteria for depression. By the time of 3 month after stroke, 238 had finished the follow-up and included in our study. Totally, 65 out of the 238 patients were diagnosed as depression (27.3%; 95% CI 19.6–35.4%). The results showed significantly higher HCY levels in patients with depression [21.4 (IQR 16.5–23.4) mmol/L vs. 14.1 (IQR 11.2–18.5) mmol/L, P < 0.0001) at admission than patients without depression. In multivariate logistic regression analysis, HCY was an independent predictor of PSD with an adjusted OR of 1.07 (95% CI 1.01–1.22; P = 0.013). Based on the ROC curve, the optimal cut-off value of serum HCY levels as an indicator for prediction of PSD was projected to be 16.5 mmol/L, which yielded a sensitivity of 82.5% and a specificity of 63.6%, with the area under the curve at 0.745 (95% CI 0.672–0.818; P < 0.0001). An increased risk of PSD was associated with serum HCY levels ≥16.5 mmol/L (adjusted OR 6.13, 95% CI 3.32–14.16; P < 0.001) after adjusting for above-recorded confounders. Elevated serum levels of HCY at admission were associated with depression 3-month after stroke, suggesting that these alterations might participate in the pathophysiology of depression symptoms in stroke patients.

Keywords

Homocysteine Stroke Depression Chinese 

Notes

Acknowledgements

We also express our gratitude to all the patients, the nurses and physicians who participated in this study, and thereby made this work possible.

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Yang R, Lu B, Li T et al (2016) The relationship between high-sensitivity C-reactive protein at admission and post stroke depression: a 6-month follow-up study[J]. Int J Geriatr Psychiatry 31(3):231–239CrossRefPubMedGoogle Scholar
  2. 2.
    Cheng SY, Zhao YD, Li J et al (2014) Plasma levels of glutamate during stroke is associated with development of post-stroke depression. Psychoneuroendocrinology 47:126–135CrossRefPubMedGoogle Scholar
  3. 3.
    Folstein M, Liu T, Peter I et al (2007) The homocysteine hypothesis of depression. Am J Psychiatry 164(6):861–867CrossRefPubMedGoogle Scholar
  4. 4.
    Amin HK, El-Sayed MIK, Leheta OF (2016) Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease. Renal Fail 38(8):1267–1275CrossRefGoogle Scholar
  5. 5.
    Miwa K, Okazaki S, Yagita Y et al (2015) Increased total homocysteine levels are associated with the risk of dementia independently of cerebral small-vessel disease. Stroke 46(Suppl 1):A224Google Scholar
  6. 6.
    Smith AD, Refsum H (2016) Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr 36(1):211–239CrossRefPubMedGoogle Scholar
  7. 7.
    Balachandar V, Sureshkumar S, Mohanadevi S et al (2015) Peripheral blood markers of homocysteine, paraoxonase1 (PON1) activity and oxidative stress in autism. Int J Dev Neurosci 47:82–83CrossRefGoogle Scholar
  8. 8.
    Ganguly P, Alam SF (2015) Role of homocysteine in the development of cardiovasculardisease. Nutr J 14(1):1CrossRefGoogle Scholar
  9. 9.
    Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI (2000) Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 31:1069–1075CrossRefPubMedGoogle Scholar
  10. 10.
    Sasaki T, Watanabe M, Nagai Y, Hoshi T, Takasawa M, Nukata M, Taguchi A, Kitagawa K, Kinoshita N, Matsumoto M (2002) Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke 33:1493–1496CrossRefPubMedGoogle Scholar
  11. 11.
    Kim JM, Stewart R, Kim SW et al (2008) Predictive value of folate, vitamin B12 and homocysteine levels in late-life depression. Br J Psychiatry 192(4):268–274CrossRefPubMedGoogle Scholar
  12. 12.
    Han L, Wu Q, Wang C et al (2015) Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients a population-based. Prospective cohort study. Stroke 46(7):1777–1786CrossRefPubMedGoogle Scholar
  13. 13.
    Shi Z, Guan Y, Huo YR et al (2015) Elevated total homocysteine levels in acute ischemic stroke are associated with long-term mortality. Stroke 46(9):2419–2425CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ford AH, Flicker L, Singh U et al (2013) Homocysteine, depression and cognitive function in older adults. J Affect Disord 151(2):646–651CrossRefPubMedGoogle Scholar
  15. 15.
    Pascoe MC, Crewther SG, Carey LM et al (2012) Homocysteine as a potential biochemical marker for depression in elderly stroke survivors. Food Nutr Res. doi: 10.3402/fnr.v56i0.14973 PubMedPubMedCentralGoogle Scholar
  16. 16.
    Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh E (1993) Classification ofsubtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 inAcute Stroke Treatment. Stroke 24:35–41CrossRefPubMedGoogle Scholar
  17. 17.
    Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Hertzberg V (1989) Measurements ofacute cerebral infarction: a clinical examination scale. Stroke 20:864–870CrossRefPubMedGoogle Scholar
  18. 18.
    Sims JR, Gharai LR, Schaefer PW et al (2009) ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 72(24):2104–2110CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    First MB, Spitzer RL, Gibbon M (1995) Structured clinical interview for DSM-IV axis I disorders—patient edition (SCID-I/P, version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New YorkGoogle Scholar
  20. 20.
    Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Nabi H, Bochud M, Glaus J et al (2013) Association of serum homocysteine with major depressive disorder: results from a large population-based study. Psychoneuroendocrinology 38(10):2309–2318CrossRefPubMedGoogle Scholar
  22. 22.
    Nashaat M, Hamdi E, Mawella SA et al (2012) Homocysteine level and depression in patients with ischaemic heart disease. Egypt J Psychiatry 33(2):83CrossRefGoogle Scholar
  23. 23.
    Wu D, Wang L, Teng W et al (2015) Correlation of post-stroke fatigue with glucose, homocysteine and functional disability. Acta Neurol Scand 131(6):400–404CrossRefPubMedGoogle Scholar
  24. 24.
    Robinson RG (2003) Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 54:376–387CrossRefPubMedGoogle Scholar
  25. 25.
    Tang CZ, Zhang YL, Wang WS et al (2016) Serum levels of high-sensitivity C-reactive protein at admission are more strongly associated with poststroke depression in acute ischemic stroke than homocysteine levels. Mol Neurobiol 53(4):2152–2160CrossRefPubMedGoogle Scholar
  26. 26.
    Farner L, Wagle J, Engedal K, Flekkøy KM, Wyller TB, Fure B (2010) Depressive symptoms in stroke patients: a 13 month follow-up study of patients referred to a rehabilitation unit. J Affect Disord 127:211–218CrossRefPubMedGoogle Scholar
  27. 27.
    Jimenez I, Sobrino T, Rodriguez-Yanez M, Pouso M, Cristobo I, Sabucedo M, Castillo J (2009) High serum levels of leptin are associated with post-stroke depression. Psychol Med 39:1201–1209CrossRefPubMedGoogle Scholar
  28. 28.
    Kim JM, Stewart R, Bae KY, Kim SW, Kang HJ, Shin IS, Yoon JS (2012) Serotonergic and BDNF genes and risk of depression after stroke. J Affect Disord 136:833–840CrossRefPubMedGoogle Scholar
  29. 29.
    Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:55–68CrossRefPubMedGoogle Scholar
  30. 30.
    Obeid R, McCaddon A, Herrmann W (2007) The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med 45:1590–1606PubMedGoogle Scholar
  31. 31.
    Loureiro SO, Romão L, Alves T, Fonseca A, Heimfarth L, Moura Neto V et al (2010) Homocysteine induces cytoskeletal remodeling and production of reactive oxygen species in cultured cortical astrocytes. Brain Res 1355:151–164CrossRefPubMedGoogle Scholar
  32. 32.
    Jakubowski H, Głowacki R (2011) Chemical biology of homocysteine thiolactone and related metabolites. Adv Clin Chem 55:81–103CrossRefPubMedGoogle Scholar
  33. 33.
    Sanchez-Villegas A, Martinez-Gonzalez MA (2013) Diet, a new target to prevent depression? BMC Med 11:3CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH (2000) Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 69:228–232CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Toole JF, Malinow MR, Chambless LE et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 291(5):565–575CrossRefPubMedGoogle Scholar
  36. 36.
    Starkstein SE, Mizrahi R, Power BD (2008) Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother 9(8):1291–1298CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2017

Authors and Affiliations

  1. 1.Department of NeurologyQilu Hospital of Shandong UniversityJinanPeople’s Republic of China
  2. 2.Department of NeurologyThe People’s Hospital of Laiwu CityLaiwuPeople’s Republic of China

Personalised recommendations